parthenolide has been researched along with piplartine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| AbdulSalam, SF; Landero-Figueroa, J; Merino, EJ; Mulloy, JC; Pullen, ED; Vadukoot, AK; Wunderlich, M | 1 |
| Ashton, JM; Balys, M; Becker, MW; Benes, C; Callahan, KP; Corbett, C; Crooks, PA; Greninger, P; Hagen, FK; Jordan, CT; Lagadinou, ED; Li, Z; Liesveld, JL; Minhajuddin, M; Munger, J; Neering, SJ; O'Dwyer, KM; Pei, S; Settleman, J; Shi, L; Ye, H | 1 |
1 trial(s) available for parthenolide and piplartine
| Article | Year |
|---|---|
Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD34; Dioxolanes; Female; Glutamate-Cysteine Ligase; Glutathione; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Humans; Leukemia, Myeloid, Acute; Male; Oxidation-Reduction; Oxidative Stress; Sesquiterpenes; Tumor Cells, Cultured | 2013 |
1 other study(ies) available for parthenolide and piplartine
| Article | Year |
|---|---|
Design of a hydrogen peroxide-activatable agent that specifically targets cancer cells.
Topics: Amines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclization; Drug Design; Humans; Hydrogen Peroxide; Kinetics; Oxidation-Reduction; Structure-Activity Relationship | 2014 |